ShareValue scores for VINEETLAB.NSE: Valuation 44, Quality 42, Growth 32, Health 44.

VINEETLAB.NSE
NSE

Vineet Laboratories Limited

₹38.70(-0.77%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

4% to 15%
Valuation
44
Fair Value
Price vs Value
Quality
42
Moderate
Business Strength
Growth
32
Weak
Revenue & Earnings
Health
44
Moderate
Financial Stability
Momentum
63
Bullish
Price Trend

Company Details

About

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026